Back to News
investment

William Blair Upgrades Biodesix (BDSX)

Fintel
Loading...
4 min read
0 likes
⚡ Quantum Brief
William Blair upgraded Biodesix (BDSX) from Market Perform to Outperform on February 27, 2026, signaling strong confidence in the biotech firm’s growth potential. Analysts project a 116.24% upside, with an average one-year price target of $33.15—nearly double its $15.33 closing price—ranging from $20.20 to $42.00. Biodesix forecasts $94M in annual revenue, a 16.68% year-over-year increase, though its non-GAAP EPS remains negative at -$1.22, reflecting ongoing investment. Institutional ownership rose 4.79% to 1.34M shares over three months, despite a 13.89% drop in fund holders, while the 0.10 put/call ratio suggests bullish market sentiment. Major shareholders show mixed moves: Telemark cut its stake by 26.33%, but Perceptive Advisors entered with a 100% increase, and Monashee and GSA Capital raised holdings by 10.99% and 25.03%, respectively.
AI Audio Summary
0:00 / 0:00
Click to play
quantum computing images (3).jpg
Quantum News · Media Library

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks BDSX William Blair Upgrades Biodesix (BDSX) February 28, 2026 — 05:03 am EST Written by George Maybach for Fintel-> Fintel reports that on February 27, 2026, William Blair upgraded their outlook for Biodesix (NasdaqGM:BDSX) from Market Perform to Outperform.

Analyst Price Forecast Suggests 116.24% Upside As of February 25, 2026, the average one-year price target for Biodesix is $33.15/share. The forecasts range from a low of $20.20 to a high of $42.00. The average price target represents an increase of 116.24% from its latest reported closing price of $15.33 / share. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Biodesix is 94MM, an increase of 16.68%. The projected annual non-GAAP EPS is -1.22. What is the Fund Sentiment? There are 31 funds or institutions reporting positions in Biodesix. This is an decrease of 5 owner(s) or 13.89% in the last quarter. Average portfolio weight of all funds dedicated to BDSX is 0.02%, an increase of 45.65%. Total shares owned by institutions increased in the last three months by 4.79% to 1,342K shares. The put/call ratio of BDSX is 0.10, indicating a bullish outlook. What are Other Shareholders Doing?

Telemark Asset Management holds 328K shares representing 4.12% ownership of the company. In its prior filing, the firm reported owning 414K shares , representing a decrease of 26.33%. The firm decreased its portfolio allocation in BDSX by 24.97% over the last quarter.

Standard Life Aberdeen holds 262K shares representing 3.30% ownership of the company.

Monashee Investment Management holds 112K shares representing 1.41% ownership of the company. In its prior filing, the firm reported owning 100K shares , representing an increase of 10.99%. Perceptive Advisors holds 109K shares representing 1.37% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.

Gsa Capital Partners Llp holds 64K shares representing 0.81% ownership of the company. In its prior filing, the firm reported owning 48K shares , representing an increase of 25.03%. The firm increased its portfolio allocation in BDSX by 23.98% over the last quarter. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Biodesix, Inc.-> Find out what the Options Markets think of Biodesix, Inc.-> See our take on Biodesix, Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned BDSX More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Read Original

Source Information

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.